Annual Meeting 2026 Press Program | Official Media Newsroom

The landscape of precision oncology is shifting toward targets once deemed “undruggable,” as the American Association for Cancer Research (AACR) prepares to unveil critical data at its 117th Annual Meeting this April. For patients with advanced lung and ovarian cancers, the upcoming presentations represent more than just academic milestones—they signal a potential pivot in standard-of-care treatments for some of the most resistant forms of the disease.

The Deep Dive: Breaking the “Undruggable” Barrier

For decades, the KRAS protein—a molecular switch that, when mutated, drives uncontrolled cell growth—was considered an impossible target for drug development due to its smooth surface and lack of binding pockets. The emergence of inhibitors like Elisrasib and Zoldonrasib marks a new era of “next-generation” precision medicine.

While G12C inhibitors have already begun to enter the clinic, the focus on the G12D mutation (targeted by Zoldonrasib) is particularly significant. G12D is one of the most common KRAS mutations across several cancer types, including pancreatic and colorectal cancers. By demonstrating “effective and durable responses” in lung cancer, researchers are proving that the strategy used for G12C can be replicated across other mutation profiles, effectively widening the net of patients who can benefit from targeted therapy.

Simultaneously, the introduction of a new Antibody-drug Conjugate (ADC) for platinum-resistant ovarian cancer addresses a critical gap in oncology. Platinum-based chemotherapies are the gold standard for ovarian cancer, but when resistance develops, options become limited and toxicity increases. ADCs act as “biological missiles,” using an antibody to find a specific marker on a cancer cell and delivering a potent payload of chemotherapy directly inside, minimizing collateral damage to healthy tissue.

The Forward Look: What to Watch

The data presented at the AACR Annual Meeting typically serves as the precursor to pivotal Phase III clinical trials. Investors and clinicians should watch for three specific developments following the April 17-22 event:

First, look for combination therapy trials. It is highly likely that researchers will begin testing KRAS inhibitors in tandem with immunotherapy (checkpoint inhibitors) to prevent the tumor from developing resistance to the drug.

Second, keep an eye on regulatory fast-tracking. If the “durable responses” mentioned for Zoldonrasib and Elisrasib are statistically significant, we can expect applications for FDA Breakthrough Therapy Designation, which would accelerate the timeline for patient access.

Finally, the success of the new ADC in ovarian cancer may trigger a cross-indication surge, where the same drug is tested against other platinum-resistant solid tumors, potentially expanding the market and the clinical utility of the platform.